Gold prices edge higher on raised Fed rate cut hopes
BOSTON - 908 Devices Inc. (NASDAQ:MASS), a company specializing in handheld chemical analysis tools, reported a preliminary revenue growth of 55% from continuing operations for the first quarter of 2025. The revenue is estimated to be at least $11.5 million, up from $7.4 million in the same period last year. According to InvestingPro data, the company’s market capitalization stands at $156.16 million, with analysts projecting an 8% revenue decline for the full year 2025.
The increase does not include around $1.1 million from the desktop portfolio, which was divested on March 4, 2025. These funds will appear under discontinued operations in the quarterly report. The company’s cash position, including cash equivalents and marketable securities, stood at approximately $124 million at quarter’s end, with an additional $4.0 million in escrow from the divestiture. InvestingPro analysis shows the company maintains a strong current ratio of 4.1, with liquid assets exceeding short-term obligations, though it’s currently burning through cash reserves.
CEO Kevin J. Knopp highlighted the company’s shift in focus towards their advanced chemical detection strategy and expressed confidence in achieving Adjusted EBITDA positivity by the fourth quarter of 2025.
The financial results are still subject to the completion of financial closing procedures and internal reviews. 908 Devices will provide a detailed discussion of its financial results and outlook for the rest of the year during a conference call and live audio webcast on May 13, 2025.
This announcement is based on a press release statement and contains forward-looking statements that involve risks and uncertainties. The actual results may differ materially from those projected due to various factors, as detailed in the company’s SEC filings.
In other recent news, 908 Devices has reported notable developments that are capturing investor attention. The company announced a $1.7 million order from the Ukrainian Ministry of Health for its MX908 handheld mass spectrometry devices, which will be shipped in the first quarter of 2025. This order highlights the growing demand for 908 Devices’ technology in international markets. In its latest earnings report, 908 Devices posted fourth-quarter revenue of $18.8 million, marking a 31% increase year-over-year, although it fell short of the $21.28 million consensus estimate. The adjusted earnings per share were -$0.56, missing the expected -$0.23 per share.
The company also completed a divestiture of its desktop portfolio to Repligen for $70 million, a strategic move aimed at focusing on high-growth handheld markets. Stifel analysts maintained their Buy rating on 908 Devices, with a price target of $6, noting the positive impact of the divestiture on the company’s profitability and balance sheet. For the full year 2024, 908 Devices reported revenue of $59.6 million, with significant growth in its handheld and recurring revenue segments. Looking forward, the company projects 2025 revenue from continuing operations to be between $53 million and $55 million, with expectations of further growth acceleration in 2026. The company concluded 2024 with $69.6 million in cash and no debt, positioning it well for future growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.